Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.58 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26306456 | 0.86 | HTT (0.64) | HTTSMN1; SMN2NPC1RAB9AKCNMA1 | |
| SCHEMBL2507014 | 0.84 | NPC1 (0.61) | HTTSMN1; SMN2NPC1RAB9AATM | |
| SCHEMBL30733199 | 0.82 | MAPT (0.67) | HTTSMN1; SMN2RAB9AGAANCOA1 | |
| SCHEMBL11995707 | 0.82 | MAPT (0.67) | HTTSMN1; SMN2RAB9AGAANCOA1 | |
| SCHEMBL16973835 | 0.82 | CYP1A2 (0.59) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL394289 | 0.81 | KCNMA1 (0.79) | HTTSMN1; SMN2GAANCOA1NCOA3 | |
| SCHEMBL8299753 | 0.81 | TDP1 (0.68) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL28358581 | 0.81 | HTT (0.56) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL9867402 | 0.80 | KDR (0.70) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL2506958 | 0.80 | MEN1 (0.54) | HTTSMN1; SMN2RAB9AGAANCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704117-B1 | AZABICYCLO DERIVATIVES FOR TREATING OCULAR DISORDERS | ALCON INC (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12247028-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2025-03-11 | — | — | US | disclosed |
| US-20240132497-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2024-04-25 | — | — | US | disclosed |
| US-11884666-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2024-01-30 | — | — | US | disclosed |
| US-20220267328-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2022-08-25 | — | — | US | disclosed |
| US-11306090-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20210179616-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2021-06-17 | — | — | US | disclosed |
| US-20210179616-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2021-06-17 | — | — | US | disclosed |
| CN-111247147-A | Azabicyclo and diazepatriene derivatives useful for treating ocular disorders | 爱尔康公司 | 2020-06-05 | — | — | CN | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2217606-A1 | SOLUBILIZED THIAZOLOPYRIDINES | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2010071853-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20070265251-A1 | Muscarinic Antagonists With Parp and Sir Modulating Activity as Cytoprotective Agents | PROTEOSYS AG (DE) | 2007-11-15 | — | — | US | disclosed |
| CN-101005845-A | Muscarinic antagonists with PARP and SIR modulatng activity as agents for inflammatory diseases | PROTEOSYS AG (DE) | 2007-07-25 | — | — | CN | disclosed |
| EP-1768674-A1 | MUSCARINIC ANTAGONISTS WITH PARP AND SIR MODULATING ACTIVITY AS CYTOPROTECTIVE AGENTS | ProteoSys AG (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008118-A1 | MUSCARINIC ANTAGONISTS WITH PARP AND SIR MODULATING ACTIVITY AS CYTOPROTECTIVE AGENTS | PROTEOSYS AG (DE) | 2006-01-26 | — | — | WO | disclosed |
| US-5077408-A | PROCESS FOR THE SYNTHESIS OF OXAZOLOPYRIDINE COMPOUNDS | SCIENCE ET ORGANISATION (FR) | 1991-12-31 | — | — | US | disclosed |
| US-4308206-A | Process for preparing derivatives of 5,11-dihydro-6h-pyrido[2,3-b][1,4]-benzodiazepin-6-one, and the final derivatives and synthesis intermediates obtained thereby | MICROSULES ARGENTINA S.A. DE S.C.I.I.A. (AR) | 1981-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884666-B2 | Azabicyclo and diazepine derivatives | CHRM3, CHRM5, CHRNA5 | HTT 4056/4885SMN1; SMN2 4479/4885NPC1 1376/4885 |
| US-20070265251-A1 | Muscarinic Antagonists With Parp and Sir Modulating Activity as Cytoprotective Agents | CHRM1, PARP1, CHRM2 | HTT 1194/4885SMN1; SMN2 1498/4885NPC1 2893/4885 |
| US-20240132497-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | CHRM3, CHRM5, CHRNA5 | HTT 4056/4885SMN1; SMN2 4479/4885NPC1 1376/4885 |
| US-20210179616-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | CHRM3, CHRM5, CHRNA5 | HTT 4056/4885SMN1; SMN2 4479/4885NPC1 1376/4885 |
| US-20220267328-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | CHRM3, CHRM5, CHRNA5 | HTT 4056/4885SMN1; SMN2 4479/4885NPC1 1376/4885 |
| US-12247028-B2 | Azabicyclo and diazepine derivatives | CHRM3, CHRM5, CHRNA5 | HTT 4056/4885SMN1; SMN2 4479/4885NPC1 1376/4885 |
| US-11306090-B2 | Azabicyclo and diazepine derivatives | CHRM3, CHRM5, CHRNA5 | HTT 4056/4885SMN1; SMN2 4479/4885NPC1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.